drugset / Trial / NCT05780307
IMM2520, a PD-L1 and CD47 Bispecific Antibody in Patients With Advanced Solid Tumors
Phase 1
Unknown
48 enrolled
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Shandong Cancer Hospital and Institute · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a multi-center, open-label, dose-escalation and cohort-expansion phase I clinical study to evaluate the safety and tolerability, pharmacokinetics profile, efficacy and immunogenicity of IMM2520 in subjects with advanced solid tumors.
Timeline
- Start
- 2023-03-23
- Primary completion
- 2024-03-10
- Completion
- 2025-10-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IMM2520 | Monoclonal antibody | 0.1 mg/kg | Intravenous |
| Subject | IMM2520 | Monoclonal antibody | 0.4 mg/kg | Intravenous |
| Subject | IMM2520 | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | IMM2520 | Monoclonal antibody | 2 mg/kg | Intravenous |
| Subject | IMM2520 | Monoclonal antibody | 4 mg/kg | Intravenous |
| Subject | IMM2520 | Monoclonal antibody | 6 mg/kg | Intravenous |